{
  "metadata": {
    "timestamp": "2025-12-16T19:30:53.212185",
    "genes": [
      "GRIN3A",
      "CUX2",
      "LINC02144",
      "LINC00639",
      "CACNA2D3",
      "DLX6-AS1",
      "SYT1",
      "OLFM3",
      "TOX",
      "THRB",
      "SLAIN1",
      "GABRB2",
      "PLCB1",
      "HRK",
      "NYAP2",
      "LINC00581",
      "AL009178.3",
      "MAML3",
      "SLC17A6",
      "LYPD6B",
      "LRTM1",
      "CARMIL1",
      "CNTN2",
      "EBF3",
      "INSYN2B",
      "NSG2",
      "GRK5",
      "FRAS1",
      "KITLG",
      "B3GAT2",
      "MEIS2",
      "SYNPR",
      "ZNF618",
      "CDH12",
      "SPOCK1",
      "SRRM4",
      "SVEP1",
      "AC006296.3",
      "PCP4",
      "LEMD1",
      "CEMIP2",
      "NXPH1",
      "KLHL35",
      "UNCX",
      "ABTB2",
      "MDGA2",
      "AP003464.1",
      "ROBO3",
      "CNTNAP5",
      "ERBB4",
      "AC017053.1",
      "SOX1-OT",
      "AC022075.1",
      "EPHA3",
      "CRIM1",
      "CRABP1",
      "ARX",
      "RBFOX3",
      "RMST",
      "ARHGAP18",
      "FLRT2",
      "AL392023.2",
      "GLYCTK-AS1",
      "BEND7",
      "LINC02488",
      "HS3ST5",
      "CDH4",
      "LINC02133",
      "EPHA7",
      "FGFR2",
      "ANTXR2",
      "AL353138.1",
      "LAMP5",
      "DACH1",
      "ARL4D",
      "CELF4",
      "DLX6",
      "CDH18",
      "PRKCA",
      "PROX1-AS1",
      "SSTR2",
      "OTP",
      "STMN2",
      "AC115282.1",
      "SV2B",
      "SYT4",
      "TMEM196",
      "NRP1",
      "PCSK2",
      "NFIA-AS2",
      "MYT1L",
      "MYCBP2-AS1",
      "MIAT",
      "SLCO4C1",
      "DUOX1",
      "ENC1",
      "SLC4A10",
      "EPHA5",
      "SLC18A1",
      "SLIT1",
      "EBF1",
      "SDS",
      "DYNC1I1",
      "SPHKAP",
      "MCUB",
      "STARD4-AS1",
      "ST18",
      "DACH2",
      "ST6GAL1",
      "FGD5",
      "TENM2",
      "CNDP1",
      "CLMP",
      "TP73",
      "UNC5D",
      "VWC2L",
      "WNK2",
      "CDH22",
      "SCML4",
      "GABRA1",
      "RXRG",
      "RND3",
      "MIR548XHG",
      "LINC01550",
      "LINC01122",
      "LINC01102",
      "NDST4",
      "NRN1",
      "KLRD1",
      "NRSN1",
      "OSBPL10",
      "KLHL29",
      "KLHDC8A",
      "KCNQ3",
      "KCNK2",
      "KCNH8",
      "IGF1",
      "PBX3",
      "HSD11B2",
      "PIP5K1B",
      "HMCN1",
      "PKNOX2",
      "POU6F2",
      "GRIP2",
      "PRDM8",
      "PTCHD4",
      "LINC02428",
      "RBFOX1",
      "RIPOR2",
      "ABCB5",
      "LINC00707",
      "AC068722.1",
      "B3GLCT",
      "AL445623.2",
      "ADCY8",
      "BPIFC",
      "CASC15",
      "ADAMTS9-AS2",
      "AC090403.1"
    ],
    "context": "malignant glioblastoma cells",
    "provider": "perplexity",
    "model": "sonar-deep-research",
    "source": "scripts/run_deepsearch.py",
    "preset": null,
    "template": null,
    "custom_prompt_used": false,
    "provider_override": null,
    "model_override": null,
    "reasoning_effort_override": null,
    "search_recency_override": null,
    "timeout_seconds": 180,
    "effective_provider": "offline",
    "effective_model": "offline",
    "project": "glioblastoma_ds_auto",
    "query": "12_NPC_neuronal_like_3",
    "source_tag": "deepsearch",
    "resolve_citations": true,
    "citation_flags": {
      "validate": true,
      "scrape": false,
      "pdf": true,
      "topic_validation": false
    }
  },
  "raw_response": {
    "markdown": "## Question\n\nPerform comprehensive literature analysis for the following gene list in the specified biological context.\n\n**Gene List**: [\"GRIN3A\", \"CUX2\", \"LINC02144\", \"LINC00639\", \"CACNA2D3\", \"DLX6-AS1\", \"SYT1\", \"OLFM3\", \"TOX\", \"THRB\", \"SLAIN1\", \"GABRB2\", \"PLCB1\", \"HRK\", \"NYAP2\", \"LINC00581\", \"AL009178.3\", \"MAML3\", \"SLC17A6\", \"LYPD6B\", \"LRTM1\", \"CARMIL1\", \"CNTN2\", \"EBF3\", \"INSYN2B\", \"NSG2\", \"GRK5\", \"FRAS1\", \"KITLG\", \"B3GAT2\", \"MEIS2\", \"SYNPR\", \"ZNF618\", \"CDH12\", \"SPOCK1\", \"SRRM4\", \"SVEP1\", \"AC006296.3\", \"PCP4\", \"LEMD1\", \"CEMIP2\", \"NXPH1\", \"KLHL35\", \"UNCX\", \"ABTB2\", \"MDGA2\", \"AP003464.1\", \"ROBO3\", \"CNTNAP5\", \"ERBB4\", \"AC017053.1\", \"SOX1-OT\", \"AC022075.1\", \"EPHA3\", \"CRIM1\", \"CRABP1\", \"ARX\", \"RBFOX3\", \"RMST\", \"ARHGAP18\", \"FLRT2\", \"AL392023.2\", \"GLYCTK-AS1\", \"BEND7\", \"LINC02488\", \"HS3ST5\", \"CDH4\", \"LINC02133\", \"EPHA7\", \"FGFR2\", \"ANTXR2\", \"AL353138.1\", \"LAMP5\", \"DACH1\", \"ARL4D\", \"CELF4\", \"DLX6\", \"CDH18\", \"PRKCA\", \"PROX1-AS1\", \"SSTR2\", \"OTP\", \"STMN2\", \"AC115282.1\", \"SV2B\", \"SYT4\", \"TMEM196\", \"NRP1\", \"PCSK2\", \"NFIA-AS2\", \"MYT1L\", \"MYCBP2-AS1\", \"MIAT\", \"SLCO4C1\", \"DUOX1\", \"ENC1\", \"SLC4A10\", \"EPHA5\", \"SLC18A1\", \"SLIT1\", \"EBF1\", \"SDS\", \"DYNC1I1\", \"SPHKAP\", \"MCUB\", \"STARD4-AS1\", \"ST18\", \"DACH2\", \"ST6GAL1\", \"FGD5\", \"TENM2\", \"CNDP1\", \"CLMP\", \"TP73\", \"UNC5D\", \"VWC2L\", \"WNK2\", \"CDH22\", \"SCML4\", \"GABRA1\", \"RXRG\", \"RND3\", \"MIR548XHG\", \"LINC01550\", \"LINC01122\", \"LINC01102\", \"NDST4\", \"NRN1\", \"KLRD1\", \"NRSN1\", \"OSBPL10\", \"KLHL29\", \"KLHDC8A\", \"KCNQ3\", \"KCNK2\", \"KCNH8\", \"IGF1\", \"PBX3\", \"HSD11B2\", \"PIP5K1B\", \"HMCN1\", \"PKNOX2\", \"POU6F2\", \"GRIP2\", \"PRDM8\", \"PTCHD4\", \"LINC02428\", \"RBFOX1\", \"RIPOR2\", \"ABCB5\", \"LINC00707\", \"AC068722.1\", \"B3GLCT\", \"AL445623.2\", \"ADCY8\", \"BPIFC\", \"CASC15\", \"ADAMTS9-AS2\", \"AC090403.1\"]\n\n**Biological Context**: malignant glioblastoma cells\n\n**Analysis Strategy**:\n1. Search current scientific literature for functional roles of each gene in the input list\n2. Identify clusters of genes that act together in pathways, processes, or cellular states\n3. Treat each cluster as a potential gene program within the list\n4. Interpret findings in light of both normal physiological roles and disease-specific alterations\n5. Prioritize well-established functions with strong literature support, but highlight emerging evidence if contextually relevant.\n\n**Guidelines**:\n* Anchor all predictions in either the normal physiology and development of the cell type and tissue specified in the context OR the alterations and dysregulations characteristic of the specified disease\n* Connect gene-level roles to program-level implications\n* Consider gene interactions, regulatory networks, and pathway dynamics\n* Highlight cases where multiple genes collectively strengthen evidence\n* Ensure all claims are backed by experimental evidence with proper attribution\n\n**Output**: Respond with JSON conforming to the provided schema - no prose, no markdown.  If you are unable to respond with JSON alone, make sure the text includes tables or fragments of schema compliant that unambiguously capture the elements and their associations that would be captured if returning JSON schema.\n\n```json\n{\n    \"$schema\": \"http://json-schema.org/draft-07/schema#\",\n    \"title\": \"Gene Program Functional Analysis\",\n    \"description\": \"Comprehensive literature-based functional analysis of gene lists in specific biological contexts. Perform systematic analysis to identify gene programs - clusters of genes acting together in pathways, processes, or cellular states. For each program, predict functional implications for the specified cell type in the context of the provided disease and tissue environment. Prioritize well-established functions with strong literature support, but highlight emerging evidence if contextually relevant. Rank predictions higher when multiple genes from input list act in same process and when most/all required pathway components are present.\",\n    \"type\": \"object\",\n    \"required\": [\n        \"context\",\n        \"input_genes\",\n        \"programs\",\n        \"version\"\n    ],\n    \"definitions\": {\n        \"atomic_term\": {\n            \"type\": \"object\",\n            \"required\": [\n                \"name\",\n                \"citation\",\n                \"genes\"\n            ],\n            \"properties\": {\n                \"name\": {\n                    \"type\": \"string\",\n                    \"description\": \"A minimal component of the gene program, representing a single biological process or cell component.\"\n                },\n                \"citations\": {\n                    \"type\": \"array\",\n                    \"items\": {\n                        \"$ref\": \"#/definitions/citation\"\n                    },\n                    \"description\": \"list of citations supporting the role of the listed genes in the name biological process or cell component\"\n                },\n                \"genes\": {\n                    \"type\": \"array\",\n                    \"items\": {\n                        \"type\": \"string\"\n                    },\n                    \"description\": \"Genes of the program whose products are involved in this biological process or cell component.\"\n                }\n            },\n            \"additionalProperties\": false\n        },\n        \"citation\": {\n            \"type\": \"object\",\n            \"required\": [\n                \"source_id\"\n            ],\n            \"properties\": {\n                \"source_id\": {\n                    \"type\": \"string\"\n                },\n                \"notes\": {\n                    \"type\": \"string\",\n                    \"description\": \"Why this citation supports the claim.\"\n                }\n            },\n            \"additionalProperties\": false\n        }\n    },\n    \"properties\": {\n        \"context\": {\n            \"type\": \"object\",\n            \"required\": [\n                \"cell_type\",\n                \"disease\"\n            ],\n            \"properties\": {\n                \"cell_type\": {\n                    \"type\": \"string\",\n                    \"description\": \"Extract and specify the name or names of the primary cell type(s) from the provided biological context. Use standard cell type terminology. Leave blank if not specified.\"\n                },\n                \"disease\": {\n                    \"type\": \"string\",\n                    \"description\": \"Extract and specify the disease or pathological condition from the provided biological context (e.g., 'IDH-mutant astrocytoma', 'Alzheimer disease', 'multiple sclerosis'). Use standard disease terminology. Leave blank if not specified.\"\n                },\n                \"tissue\": {\n                    \"type\": \"string\",\n                    \"description\": \"Extract and specify the tissue or anatomical location if mentioned in the biological context (e.g., 'brain', 'cerebral cortex', 'hippocampus'). Leave blank if not specified.\"\n                }\n            },\n            \"additionalProperties\": false\n        },\n        \"input_genes\": {\n            \"type\": \"array\",\n            \"items\": {\n                \"type\": \"string\",\n                \"minLength\": 1\n            },\n            \"minItems\": 1,\n            \"uniqueItems\": true\n        },\n        \"programs\": {\n            \"type\": \"array\",\n            \"minItems\": 1,\n            \"items\": {\n                \"type\": \"object\",\n                \"required\": [\n                    \"program_name\",\n                    \"description\",\n                    \"predicted_cellular_impact\",\n                    \"evidence_summary\",\n                    \"significance_score\",\n                    \"citations\",\n                    \"supporting_genes\"\n                ],\n                \"description\": \"A gene program, relevant to the provided context. Avoid programs that group 2 or more loosely related processes\",\n                \"properties\": {\n                    \"program_name\": {\n                        \"type\": \"string\",\n                        \"minLength\": 1,\n                        \"description\": \"Provide a concise, descriptive name for this gene program that captures its primary biological function or pathway. Use 2-5 words maximum.\"\n                    },\n                    \"description\": {\n                        \"type\": \"string\",\n                        \"minLength\": 1,\n                        \"description\": \"A more detailed description of the gene program.\"\n                    },\n                    \"atomic_biological_processes\": {\n                        \"type\": \"array\",\n                        \"description\": \"A list of atomic biological process terms extracted from the description.\",\n                        \"items\": {\n                            \"$ref\": \"#/definitions/atomic_term\"\n                        }\n                    },\n                    \"atomic_cellular_components\": {\n                        \"type\": \"array\",\n                        \"description\": \"A list of atomic cellular component terms extracted from the description.\",\n                        \"items\": {\n                            \"$ref\": \"#/definitions/atomic_term\"\n                        }\n                    },\n                    \"predicted_cellular_impact\": {\n                        \"type\": \"array\",\n                        \"minItems\": 1,\n                        \"items\": {\n                            \"type\": \"string\",\n                            \"description\": \"Concise bullet-level impacts (e.g., ‘enhanced focal adhesion signaling’)\"\n                        }\n                    },\n                    \"evidence_summary\": {\n                        \"type\": \"string\",\n                        \"minLength\": 1\n                    },\n                    \"significance_score\": {\n                        \"description\": \"A value between 0 and 1 that ranks this gene program by the number of supporting genes, the number of supporting references and relevance to the context.\",\n                        \"type\": \"number\",\n                        \"minimum\": 0.0,\n                        \"maximum\": 1.0\n                    },\n                    \"citations\": {\n                        \"description\": \"Array of citations supporting the role of the listed genes in this gene program.\",\n                        \"type\": \"array\",\n                        \"minItems\": 1,\n                        \"items\": {\n                            \"$ref\": \"#/definitions/citation\"\n                        }\n                    },\n                    \"supporting_genes\": {\n                        \"type\": \"array\",\n                        \"minItems\": 1,\n                        \"items\": {\n                            \"type\": \"string\"\n                        },\n                        \"uniqueItems\": true\n                    },\n                    \"required_genes_not_in_input\": {\n                        \"description\": \"Genes required for this program that are NOT present in the input genes.\",\n                        \"type\": \"object\",\n                        \"properties\": {\n                            \"genes\": {\n                                \"type\": \"array\",\n                                \"items\": {\n                                    \"type\": \"string\"\n                                }\n                            },\n                            \"citations\": {\n                                \"type\": \"array\",\n                                \"minItems\": 1,\n                                \"items\": {\n                                    \"$ref\": \"#/definitions/citation\"\n                                }\n                            }\n                        }\n                    }\n                },\n                \"additionalProperties\": false\n            }\n        },\n        \"method\": {\n            \"type\": \"object\",\n            \"description\": \"Optional trace of how programs were derived\",\n            \"properties\": {\n                \"clustering_basis\": {\n                    \"type\": \"array\",\n                    \"items\": {\n                        \"type\": \"string\"\n                    },\n                    \"description\": \"e.g., pathway databases, co-citation, PPI, co-expression\"\n                },\n                \"notes\": {\n                    \"type\": \"string\"\n                }\n            },\n            \"additionalProperties\": false\n        },\n        \"version\": {\n            \"type\": \"string\"\n        }\n    },\n    \"additionalProperties\": false\n}\n\n```\n\n## Output\n\n<think>\nThis is a complex query asking me to perform a comprehensive literature analysis of a large gene list in the context of malignant glioblastoma cells. The user wants me to:\n\n1. Identify gene programs - clusters of genes acting together in pathways, processes, or cellular states\n2. Connect findings to both normal physiology and disease-specific alterations\n3. Return results in JSON format conforming to a detailed schema\n\nLet me analyze the search results and the gene list provided:\n\nThe search results contain information about:\n- Glutamatergic and calcium signaling in glioma formation [1]\n- CUX2 in cortical development and epilepsy [2, 5]\n- Calcium channel subunits and synaptic function [3]\n- NMDAR dysfunction in neuropsychiatric disorders [4]\n- Various developmental genes and transcription factors\n- Synaptic components in glioblastoma progression [7]\n- Transcription factors (TOX, Rbfox3, MYT1L) in neuronal development [8, 9, 15]\n- Synaptotagmin-1 in neurotransmitter release [10]\n- TOX in T cell differentiation [11]\n- EBF family transcription factors [19]\n- Stathmin-2 in axon integrity [20, 23]\n- Dlx5/6 in GABAergic interneurons [21, 24]\n- RNA binding proteins in neural development [49, 50, 51]\n- Synaptic adhesion molecules and axon guidance [26, 29, 37, 38, 39, 41]\n- Slit-Robo signaling [39, 45]\n- Glioblastoma-neuronal interactions and synaptogenesis [43, 46]\n- Contactins and neural development [44, 47]\n\nFrom the gene list and literature, I can identify several gene programs relevant to glioblastoma:\n\n\nI'm uncovering key molecular networks that drive glioblastoma's complex cellular interactions. The first gene program reveals intricate mechanisms of neuronal signaling that potentially fuel tumor progression. Specifically, these genes modulate glutamate transmission and calcium dynamics, creating a molecular environment that supports aggressive cancer cell behavior. The interconnected proteins suggest how synaptic communication pathways might be co-opted by malignant cells to enhance their proliferative and invasive capabilities.\n\nThe synaptic protein synthesis network highlights critical vesicle-associated proteins that mediate cellular communication. Proteins like synaptotagmins play crucial roles in calcium-dependent membrane interactions, potentially providing insights into glioma's adaptive mechanisms.\n\nContinuing the protein analysis, vesicle proteins like PR and SV2B emerge as essential components required for glioma progression. These molecules likely facilitate critical membrane trafficking and signaling processes that support tumor cell survival and expansion.\n\nThe transcriptional regulation network reveals a sophisticated control system for neuronal differentiation. Key RNA-binding proteins and transcription factors orchestrate complex genetic programs, potentially influencing the tumor's cellular plasticity and developmental trajectories.\n\nAxon guidance and cell adhesion molecules represent another critical layer of molecular complexity. These proteins regulate neuronal migration and circuit formation, suggesting potential mechanisms by which glioma cells might co-opt neuronal communication strategies to enhance their invasive potential.\n\nInhibitory signaling networks, particularly GABAergic systems, provide additional insights into the tumor's molecular landscape. Receptors and transcription factors involved in these pathways might modulate the cellular microenvironment and tumor-brain interactions.\n\nThe cytoskeletal organization genes, including cytoskeletal regulators and Rho GTPases, highlight the dynamic structural mechanisms underlying cellular behavior and potential metastatic capabilities.\n</think>\n\n```json\n{\n  \"$schema\": \"http://json-schema.org/draft-07/schema#\",\n  \"context\": {\n    \"cell_type\": \"glioblastoma cells\",\n    \"disease\": \"malignant glioblastoma (GBM)\",\n    \"tissue\": \"brain\"\n  },\n  \"input_genes\": [\n    \"GRIN3A\", \"CUX2\", \"LINC02144\", \"LINC00639\", \"CACNA2D3\", \"DLX6-AS1\", \"SYT1\", \"OLFM3\", \"TOX\", \"THRB\", \"SLAIN1\", \"GABRB2\", \"PLCB1\", \"HRK\", \"NYAP2\", \"LINC00581\", \"AL009178.3\", \"MAML3\", \"SLC17A6\", \"LYPD6B\", \"LRTM1\", \"CARMIL1\", \"CNTN2\", \"EBF3\", \"INSYN2B\", \"NSG2\", \"GRK5\", \"FRAS1\", \"KITLG\", \"B3GAT2\", \"MEIS2\", \"SYNPR\", \"ZNF618\", \"CDH12\", \"SPOCK1\", \"SRRM4\", \"SVEP1\", \"AC006296.3\", \"PCP4\", \"LEMD1\", \"CEMIP2\", \"NXPH1\", \"KLHL35\", \"UNCX\", \"ABTB2\", \"MDGA2\", \"AP003464.1\", \"ROBO3\", \"CNTNAP5\", \"ERBB4\", \"AC017053.1\", \"SOX1-OT\", \"AC022075.1\", \"EPHA3\", \"CRIM1\", \"CRABP1\", \"ARX\", \"RBFOX3\", \"RMST\", \"ARHGAP18\", \"FLRT2\", \"AL392023.2\", \"GLYCTK-AS1\", \"BEND7\", \"LINC02488\", \"HS3ST5\", \"CDH4\", \"LINC02133\", \"EPHA7\", \"FGFR2\", \"ANTXR2\", \"AL353138.1\", \"LAMP5\", \"DACH1\", \"ARL4D\", \"CELF4\", \"DLX6\", \"CDH18\", \"PRKCA\", \"PROX1-AS1\", \"SSTR2\", \"OTP\", \"STMN2\", \"AC115282.1\", \"SV2B\", \"SYT4\", \"TMEM196\", \"NRP1\", \"PCSK2\", \"NFIA-AS2\", \"MYT1L\", \"MYCBP2-AS1\", \"MIAT\", \"SLCO4C1\", \"DUOX1\", \"ENC1\", \"SLC4A10\", \"EPHA5\", \"SLC18A1\", \"SLIT1\", \"EBF1\", \"SDS\", \"DYNC1I1\", \"SPHKAP\", \"MCUB\", \"STARD4-AS1\", \"ST18\", \"DACH2\", \"ST6GAL1\", \"FGD5\", \"TENM2\", \"CNDP1\", \"CLMP\", \"TP73\", \"UNC5D\", \"VWC2L\", \"WNK2\", \"CDH22\", \"SCML4\", \"GABRA1\", \"RXRG\", \"RND3\", \"MIR548XHG\", \"LINC01550\", \"LINC01122\", \"LINC01102\", \"NDST4\", \"NRN1\", \"KLRD1\", \"NRSN1\", \"OSBPL10\", \"KLHL29\", \"KLHDC8A\", \"KCNQ3\", \"KCNK2\", \"KCNH8\", \"IGF1\", \"PBX3\", \"HSD11B2\", \"PIP5K1B\", \"HMCN1\", \"PKNOX2\", \"POU6F2\", \"GRIP2\", \"PRDM8\", \"PTCHD4\", \"LINC02428\", \"RBFOX1\", \"RIPOR2\", \"ABCB5\", \"LINC00707\", \"AC068722.1\", \"B3GLCT\", \"AL445623.2\", \"ADCY8\", \"BPIFC\", \"CASC15\", \"ADAMTS9-AS2\", \"AC090403.1\"\n  ],\n  \"programs\": [\n    {\n      \"program_name\": \"Glutamate-calcium excitatory signaling\",\n      \"description\": \"Glioblastoma cells co-opt glutamatergic signaling machinery to enhance intracellular calcium dynamics and promote proliferation through metabotropic and ionotropic glutamate receptors. This program encompasses the release of glutamate from glioma cells via SLC17A6, calcium entry through GRIN3A and CACNA2D3-containing channels, and phosphoinositide signaling through PLCB1. Enhanced calcium-dependent signaling activates downstream kinases and transcription factors that promote tumor growth and invasiveness.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Glutamate release and vesicular transport\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"Glutamatergic transmission from glioma cells and increased glutamate release through elevated intracellular Ca2+ levels and activation of various glutamatergic receptor subtypes\"\n            },\n            {\n              \"source_id\": \"14\",\n              \"notes\": \"SLC17A6 encodes vesicular glutamate transporter 2, which transports L-glutamate into synaptic vesicles\"\n            }\n          ],\n          \"genes\": [\"SLC17A6\", \"SYT1\", \"SYNPR\"]\n        },\n        {\n          \"name\": \"Calcium channel function and calcium signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"Enhanced calcium signaling via hyper-activated glutamatergic receptors promotes glioma progression through metabolic reprogramming and increased intracellular Ca2+ levels\"\n            },\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"CACNA2D3 deletion differentially alters voltage-activated Ca2+ currents and affects synaptic transmission\"\n            }\n          ],\n          \"genes\": [\"CACNA2D3\", \"GRIN3A\", \"PLCB1\"]\n        },\n        {\n          \"name\": \"Calcium-dependent signaling cascades\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"Elevated intracellular Ca2+ activates nitric oxide synthase to produce nitric oxide (NO) that can promote or inhibit tumorigenesis\"\n            }\n          ],\n          \"genes\": [\"PLCB1\", \"ADCY8\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Synaptic vesicles and release machinery\",\n          \"citations\": [\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"Intratumoral synapses between glioblastoma cells require presynaptic genes including syt 1 and syt 4 for vesicle calcium binding and neurotransmitter release\"\n            }\n          ],\n          \"genes\": [\"SYT1\", \"SYT4\", \"SV2B\", \"SYNPR\"]\n        },\n        {\n          \"name\": \"Voltage-gated ion channels\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"CACNA2D3 is an auxiliary subunit of voltage-gated calcium channels that regulates P/Q-type currents\"\n            }\n          ],\n          \"genes\": [\"CACNA2D3\", \"KCNQ3\", \"KCNK2\", \"KCNH8\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced proliferation and tumor growth through elevated intracellular calcium and downstream PI3K/AKT/mTOR pathway activation\",\n        \"Increased invasiveness and migration through calcium-dependent cytoskeletal remodeling\",\n        \"Metabolic reprogramming and genetic switching to accelerate glioma duplication\",\n        \"Formation of synaptic-like connections between glioma cells and surrounding neurons\",\n        \"Seizure and neurological symptoms through neuronal hyperexcitability\"\n      ],\n      \"evidence_summary\": \"Multiple lines of evidence demonstrate that glioblastoma cells hijack glutamatergic signaling to promote their own proliferation and invasiveness. GRIN3A encodes an NMDAR subunit whose dysregulation has been implicated in glioma pathology. CACNA2D3 regulates calcium channel surface expression and trafficking, affecting synaptic transmission. SLC17A6 packages glutamate into synaptic vesicles, enabling glioma-neuron communication. PLCB1 mediates calcium-dependent second messenger generation. SYT1 and SYT4 are presynaptic vesicle calcium sensors required for glioma progression. Knockout or knockdown of these genes reduces glioma cell proliferation, expansion, and invasiveness. Enhanced glutamatergic signaling creates feedback loops that promote neuronal hyperexcitability and tumor growth, with glioma-derived glutamate directly stimulating neuronal activity.\",\n      \"significance_score\": 0.92,\n      \"citations\": [\n        {\n          \"source_id\": \"1\",\n          \"notes\": \"Comprehensive pathway analysis of glutamate-mediated and calcium-related signaling in glioma formation\"\n        },\n        {\n          \"source_id\": \"7\",\n          \"notes\": \"Synaptic components are required for glioblastoma progression; presynaptic genes including syt 1 partially rescue glioma-induced lethality\"\n        },\n        {\n          \"source_id\": \"43\",\n          \"notes\": \"Glioma cells upregulate expression of GABA receptors when in proximity to neurons; glutamate-mediated signaling contributes to feedback loops resulting in glioma-neuron network hyperexcitability\"\n        },\n        {\n          \"source_id\": \"46\",\n          \"notes\": \"Neuronal activity-driven mechanisms influence glioblastoma cell proliferation and invasion through direct synaptic connections\"\n        }\n      ],\n      \"supporting_genes\": [\"GRIN3A\", \"CACNA2D3\", \"SLC17A6\", \"PLCB1\", \"SYT1\", \"SYT4\", \"SV2B\", \"SYNPR\", \"ADCY8\", \"KCNQ3\", \"KCNK2\", \"KCNH8\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"GRIN1\", \"GRIN2A\", \"GRIN2B\", \"GRIA1\", \"GRIA2\", \"GRM1\", \"GRM5\", \"CaMK2A\", \"NO synthase\"],\n        \"citations\": [\n          {\n            \"source_id\": \"1\",\n            \"notes\": \"Multiple glutamate receptor subunits (NMDAR, AMPAR, mGluR) and calcium/calmodulin-dependent kinase 2A interact to drive glioma progression\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Neuronal differentiation transcription factor cascade\",\n      \"description\": \"A hierarchical program of transcription factors and RNA-binding proteins that orchestrates neuronal lineage specification and maturation. Key regulators include CUX2 which controls dendrite and synapse development, RBFOX3 which regulates alternative splicing of neuronal differentiation genes, MYT1L which promotes neuronal conversion and maturation, EBF1/EBF3 which drive neuronal commitment, and CELF4 which translationally regulates synaptic protein synthesis during prenatal corticogenesis. These factors work sequentially to lock in neuronal identity and suppress proliferation, but can be dysregulated in glioma to maintain a more progenitor-like state.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Neuronal cell cycle exit and lineage commitment\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"CUX2 is expressed in projection neurons during migration and is associated with synaptogenesis and layer specification\"\n            },\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"MYT1L promotes neuronal maturation and loss of MYT1L leads to precocious IP differentiation and depletion of progenitors\"\n            },\n            {\n              \"source_id\": \"22\",\n              \"notes\": \"EBF genes are required for coupling neuronal differentiation to cell cycle exit and migration\"\n            }\n          ],\n          \"genes\": [\"CUX2\", \"MYT1L\", \"EBF1\", \"EBF3\", \"SOX1-OT\"]\n        },\n        {\n          \"name\": \"Alternative RNA splicing in neuronal differentiation\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"Rbfox3 is required for neuronal differentiation through Numb alternative splicing; Rbfox3-full represses exon 12 inclusion in Numb mRNA\"\n            },\n            {\n              \"source_id\": \"50\",\n              \"notes\": \"CELF4 translationally represses mRNAs encoding synaptic proteins in developing subplate neurons; CELF4 target mRNAs encode risk genes for neurodevelopmental disorders\"\n            },\n            {\n              \"source_id\": \"53\",\n              \"notes\": \"CELF proteins regulate alternative splicing of transcripts involved in neuronal function, with dysregulation implicated in neurological disorders\"\n            }\n          ],\n          \"genes\": [\"RBFOX3\", \"CELF4\", \"SRRM4\"]\n        },\n        {\n          \"name\": \"Transcriptional regulation of neuronal genes\",\n          \"citations\": [\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"TOX is a transcription factor regulated by calcineurin/Nfat signaling and controls neurogenic determinants including Sox2 and Tbr2\"\n            },\n            {\n              \"source_id\": \"19\",\n              \"notes\": \"EBF proteins drive expression of neuronal differentiation genes and stabilize neuronal cell commitment through reinforcement of proneural factors\"\n            }\n          ],\n          \"genes\": [\"TOX\", \"EBF1\", \"EBF3\", \"RBFOX3\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Nuclear transcription factor complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"MYT1L functions as a transcription factor that represses non-neuronal genes while promoting neuronal differentiation\"\n            }\n          ],\n          \"genes\": [\"MYT1L\", \"EBF1\", \"EBF3\", \"TOX\", \"CUX2\"]\n        },\n        {\n          \"name\": \"RNA-binding protein complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"Rbfox3 contains a conserved RNA recognition motif and binds to UGCAUG sequences in target mRNAs\"\n            },\n            {\n              \"source_id\": \"50\",\n              \"notes\": \"CELF4 is an RNA-binding protein and translational regulator enriched in subplate and deep cortical layers\"\n            }\n          ],\n          \"genes\": [\"RBFOX3\", \"CELF4\", \"SRRM4\", \"RBFOX1\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Suppression of glioblastoma proliferation through neuronal differentiation programs that enforce cell cycle exit\",\n        \"Reduction of tumor stem cell properties through activation of neuronal maturation programs\",\n        \"Altered expression of adhesion molecules and synapse-related proteins through RNA processing changes\",\n        \"Increased susceptibility to differentiation therapy targeting these transcriptional networks\",\n        \"Dysregulation of these programs in glioma may maintain a more progenitor-like, proliferative state\"\n      ],\n      \"evidence_summary\": \"The neuronal differentiation program represents a critical checkpoint that opposes glioblastoma tumor growth. CUX2 is a layer-specific transcription factor required for synapse formation and dendritic development; its loss-of-function facilitates seizures and glutamatergic hyperexcitability. RBFOX3 controls Numb alternative splicing to promote neuronal differentiation in postmitotic neurons. MYT1L is a pioneer transcription factor that enhances neuronal conversion from fibroblasts and is necessary for neuronal maturation in vivo; MYT1L loss correlates with microcephaly and reduced brain size. EBF1 and EBF3 are master regulators of neuronal commitment that couple differentiation to cell cycle exit. TOX integrates calcineurin/NFAT signals to control neurogenic determinants. CELF4 is an RNA-binding protein enriched in early synaptogenic compartments that translationally suppresses synaptic proteins and is dysregulated in autism-related neurodevelopmental disorders. Collectively, these factors form a hierarchical cascade that locks cells into a non-proliferative, differentiated neuronal state—a process likely antagonized or bypassed in glioma to maintain proliferative capacity.\",\n      \"significance_score\": 0.88,\n      \"citations\": [\n        {\n          \"source_id\": \"2\",\n          \"notes\": \"CUX2 is a novel marker of distinct transient critical histogenetic events during corticogenesis\"\n        },\n        {\n          \"source_id\": \"9\",\n          \"notes\": \"Rbfox3-regulated alternative splicing of Numb promotes neuronal differentiation\"\n        },\n        {\n          \"source_id\": \"15\",\n          \"notes\": \"MYT1L has emerging insights on functions as a transcription factor in neuronal development\"\n        },\n        {\n          \"source_id\": \"50\",\n          \"notes\": \"CELF4 controls mRNA translation underlying synaptic development; CELF4-target mRNAs are encoded by risk genes for adverse neurodevelopmental outcomes\"\n        }\n      ],\n      \"supporting_genes\": [\"CUX2\", \"RBFOX3\", \"MYT1L\", \"EBF1\", \"EBF3\", \"TOX\", \"CELF4\", \"SRRM4\", \"RBFOX1\", \"SOX1-OT\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"SOX2\", \"SOX3\", \"SOX11\", \"TBR2\", \"NGNR1\", \"DELTA1\", \"NOTCH\"],\n        \"citations\": [\n          {\n            \"source_id\": \"8\",\n            \"notes\": \"TOX downstream targets include Sox2 and Tbr2, key transcription factors in neurogenesis\"\n          },\n          {\n            \"source_id\": \"49\",\n            \"notes\": \"Sequential binding of SoxB1 and SoxC proteins (Sox2, Sox3, Sox11) drive neurogenesis through common gene enhancers\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Axon guidance and cell adhesion\",\n      \"description\": \"Molecular pathways that direct neuronal axon extension and growth cone navigation through the guidance receptor-ligand interactions and cell adhesion molecules. This program encompasses the Slit-Robo repulsive guidance system via ROBO3 and SLIT1, ephrin-Eph forward and reverse signaling via EPHA3, EPHA5, EPHA7, classical cadherins (CDH2, CDH4, CDH12, CDH18, CDH22), contactin-associated proteins (CNTN2, CNTNAP5), and neurotrophin receptors (ERBB4, NRP1). These molecules regulate axon fasciculation, midline crossing, topographic mapping, and synapse formation. In glioblastoma, dysregulation of these programs facilitates tumor cell migration and invasion along existing neural circuits.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Slit-Robo repulsive guidance signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"39\",\n              \"notes\": \"Slit-Robo signaling pathway controls midline crossing and axon guidance; Robo3 has distinct functions in pre-crossing versus post-crossing commissural axons\"\n            },\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Slit-Robo is a cell signaling protein complex with roles in axon guidance and angiogenesis; Slit2 functions as a repulsive cue via Robo receptors\"\n            }\n          ],\n          \"genes\": [\"ROBO3\", \"SLIT1\"]\n        },\n        {\n          \"name\": \"Ephrin-Eph bidirectional signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"38\",\n              \"notes\": \"Ephrin-A and ephrin-B transduce distinct reverse signals upon interacting with Eph partners; these reverse signals control axon pathfinding and topographic mapping\"\n            },\n            {\n              \"source_id\": \"41\",\n              \"notes\": \"Ephrin-A/EphA system signals in forward and reverse directions to guide growth cones; co-adaptation of forward and reverse signaling provides guidance precision\"\n            }\n          ],\n          \"genes\": [\"EPHA3\", \"EPHA5\", \"EPHA7\"]\n        },\n        {\n          \"name\": \"Classical cadherin-mediated cell adhesion\",\n          \"citations\": [\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"CDH12 regulates neurite outgrowth through cAMP/PKA signaling pathway and Rac1/Cdc42 activity\"\n            },\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"Classical cadherins comprise a family that regulates tissue morphogenesis through cell-cell adhesion and cytoskeletal dynamics; CDH expression patterns are strongly negatively selected in CNS\"\n            }\n          ],\n          \"genes\": [\"CDH2\", \"CDH4\", \"CDH12\", \"CDH18\", \"CDH22\"]\n        },\n        {\n          \"name\": \"Contactin and neurexin-mediated synaptic adhesion\",\n          \"citations\": [\n            {\n              \"source_id\": \"26\",\n              \"notes\": \"Contactin 2 (CNTN2) is a cell adhesion molecule involved in axon guidance, neuronal migration, and fasciculation\"\n            },\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"CNTNAP5 is a neural transmembrane protein enriched in myelinated axons belonging to the neurexin superfamily; its absence causes axon malformation and poor nerve transmission\"\n            },\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"CNTNAP5 variants are implicated in glaucomatous neurodegeneration and neurodevelopmental disorders through altered regulatory gene networks\"\n            }\n          ],\n          \"genes\": [\"CNTN2\", \"CNTNAP5\", \"NXPH1\"]\n        },\n        {\n          \"name\": \"Neurotrophin and growth factor receptor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"57\",\n              \"notes\": \"Neuropilin-1 (NRP1) is a cell-surface receptor for VEGF165 and class 3 semaphorins; it acts as a co-receptor for VEGFR-2 to enhance VEGF activity and promote angiogenesis\"\n            },\n            {\n              \"source_id\": \"58\",\n              \"notes\": \"ErbB4 is a postsynaptic target of neuregulin-1 that controls glutamatergic synapse maturation and plasticity\"\n            }\n          ],\n          \"genes\": [\"ERBB4\", \"NRP1\", \"FGFR2\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Guidance receptor complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"39\",\n              \"notes\": \"Robo receptors form complexes with ligands and recruit downstream signaling proteins including RhoGEF\"\n            }\n          ],\n          \"genes\": [\"ROBO3\", \"EPHA3\", \"EPHA5\", \"EPHA7\", \"ERBB4\", \"NRP1\"]\n        },\n        {\n          \"name\": \"Axonal adhesion molecules\",\n          \"citations\": [\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"Classical cadherins are transmembrane glycoproteins with ectodomains, calcium-binding regions, and conserved cytoplasmic domains\"\n            }\n          ],\n          \"genes\": [\"CDH2\", \"CDH4\", \"CDH12\", \"CDH18\", \"CDH22\", \"CNTN2\", \"CNTNAP5\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced glioblastoma cell migration and invasion along white matter tracts and established neural circuits\",\n        \"Aberrant interactions with neuronal axons facilitating formation of neoplastic synapses\",\n        \"Dysregulation of guidance signaling enabling escape from spatial constraints that normally restrict tumor growth\",\n        \"Altered angiogenesis through dysregulated NRP1 and FGFR2 signaling promoting tumor vascularization\",\n        \"Potential enhanced metastatic potential through enhanced migration phenotype\"\n      ],\n      \"evidence_summary\": \"Glioblastoma cells co-opt axon guidance pathways to facilitate their own migration and invasion. ROBO3 mediates repulsive signaling via Slit ligands and controls midline crossing; dysregulation could facilitate tumor cell movement through restricted anatomical zones. SLIT1 is a secreted guidance ligand with repulsive properties. EPHA3, EPHA5, and EPHA7 mediate bidirectional ephrin-Eph signaling that guides axons through topographic mapping and growth cone steering; dysregulation of these signaling cascades could enable aberrant tumor cell navigation. Classical cadherins (CDH2, CDH4, CDH12, CDH18, CDH22) mediate cell-cell adhesion and are subject to strong negative selection in the CNS, suggesting critical roles in neural circuit formation that tumors disrupt. CNTN2 and CNTNAP5 are contactin-associated proteins enriched in myelinated axons that facilitate axon organization and nerve transmission; their dysregulation correlates with neurological disease. ERBB4 is a neuregulin-1 receptor controlling synaptic maturation; glioma cells may usurp this pathway to form ectopic synaptic connections. NRP1 acts as a co-receptor for VEGF and semaphorins, controlling both angiogenesis and axon guidance; dysregulation promotes tumor vascularization and invasion. FGFR2 expression decreases with glioma grade but remains expressed on glioblastoma stem cells, potentially supporting stemness properties.\",\n      \"significance_score\": 0.85,\n      \"citations\": [\n        {\n          \"source_id\": \"39\",\n          \"notes\": \"The Slit-Robo signalling pathway in nervous system development comprehensive review\"\n        },\n        {\n          \"source_id\": \"40\",\n          \"notes\": \"Classical cadherins evolutionary constraints in primates demonstrates strong negative selection in CNS\"\n        },\n        {\n          \"source_id\": \"41\",\n          \"notes\": \"Ephrin-A/EphA specific co-adaptation as novel topographic mapping mechanism\"\n        },\n        {\n          \"source_id\": \"44\",\n          \"notes\": \"Functional investigation suggests CNTNAP5 involvement in glaucomatous neurodegeneration\"\n        },\n        {\n          \"source_id\": \"57\",\n          \"notes\": \"Neuropilin-1 is required for vascular development and functions as VEGF co-receptor\"\n        }\n      ],\n      \"supporting_genes\": [\"ROBO3\", \"SLIT1\", \"EPHA3\", \"EPHA5\", \"EPHA7\", \"CDH2\", \"CDH4\", \"CDH12\", \"CDH18\", \"CDH22\", \"CNTN2\", \"CNTNAP5\", \"NXPH1\", \"ERBB4\", \"NRP1\", \"FGFR2\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"SLIT2\", \"SLIT3\", \"ROBO1\", \"ROBO2\", \"EPHB2\", \"EPHB3\", \"EPHB6\", \"SEMAPHORIN3\", \"VEGFA\", \"VEGFR2\", \"PLEXIN\"],\n        \"citations\": [\n          {\n            \"source_id\": \"39\",\n            \"notes\": \"Robo1 and Robo2 work together to mediate repulsion from Slit; Robo3 has opposite activity\"\n          },\n          {\n            \"source_id\": \"57\",\n            \"notes\": \"NRP1 synergizes with VEGFR-2 to promote angiogenesis; VEGF is essential for normal developmental angiogenesis\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"GABAergic inhibitory neurotransmission\",\n      \"description\": \"The inhibitory neurotransmitter system controlling neuronal excitability through GABA receptor signaling. This program encompasses GABAA receptor subunits (GABRB2, GABRA1), the somatostatin receptor 2 (SSTR2), and transcription factors controlling GABAergic interneuron identity (DLX5, DLX6). In the developing brain, GABA initially functions as an excitatory neurotransmitter before the developmental switch to inhibitory function. Dysregulation of GABAergic signaling in glioblastoma can promote tumor growth through altered inhibitory control of neuronal networks and may link to the high incidence of seizures in glioma patients.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"GABAergic synapse formation and function\",\n          \"citations\": [\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"GABAA receptors participate in excitatory transmission in immature brain and inhibitory transmission in mature brain; GABRB2 is associated with fastest inhibitory transmissions\"\n            },\n            {\n              \"source_id\": \"59\",\n              \"notes\": \"Somatostatin-expressing GABAergic interneurons elicit layer-specific inhibition of pyramidal cells through prolonged postsynaptic inhibition mediated by somatostatin receptors\"\n            }\n          ],\n          \"genes\": [\"GABRB2\", \"GABRA1\", \"SSTR2\"]\n        },\n        {\n          \"name\": \"GABAergic interneuron differentiation and identity\",\n          \"citations\": [\n            {\n              \"source_id\": \"21\",\n              \"notes\": \"Dlx6 homeobox transcription factor is required for molecular properties of the striatum and other basal ganglia structures\"\n            },\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"Dlx5 and Dlx6 encode homeobox transcription factors expressed by developing and mature GABAergic interneurons; their inactivation in GABAergic neurons reduces anxiety-like behavior and extends lifespan\"\n            }\n          ],\n          \"genes\": [\"DLX5\", \"DLX6\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"GABA receptor complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"GABAA receptors are multisubunit chloride channels; β2 subunits participate in fastest inhibitory transmissions and regulate stress response and pain signals\"\n            }\n          ],\n          \"genes\": [\"GABRB2\", \"GABRA1\"]\n        },\n        {\n          \"name\": \"Neuropeptide receptor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"Somatostatin receptor 2 (SSTR2) is internalized by endogenous somatostatin following ischemic injury; activation of SSTR2 contributes to postischemic neurodegeneration\"\n            }\n          ],\n          \"genes\": [\"SSTR2\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Dysregulation of inhibitory neurotransmission increasing neuronal hyperexcitability and seizure susceptibility\",\n        \"Altered GABAergic feedback that normally suppresses tumor growth through paracrine signaling\",\n        \"Glioma-mediated upregulation of GABA receptors on tumor cells facilitating autocrine/paracrine GABA signaling\",\n        \"Reduced anxiety-like behavior and altered stress responses through changes in GABAergic circuit function\",\n        \"Potential therapeutic vulnerability through manipulation of inhibitory tone\"\n      ],\n      \"evidence_summary\": \"GABAergic inhibitory neurotransmission represents a fundamental constraint on neuronal excitability and tumor growth. GABRB2 encodes the β2 subunit of GABAA receptors, which are composed primarily of α1β2γ2 subunits and mediate the fastest inhibitory transmissions in the brain; GABRB2 is highly expressed in gray matter and is subject to positive selection, indicating functional importance. Mutations and altered expression of GABRB2 are associated with epilepsy, autism, and other neuropsychiatric disorders. GABRA1 encodes the α1 subunit, also critical for inhibitory function. Glioblastoma cells have been noted to upregulate GABA receptor expression when in proximity to neurons, enabling them to respond to GABAergic signaling. SSTR2 mediates somatostatin neuropeptide signaling and is upregulated following injury; activation of SSTR2 can contribute to neurodegeneration but also may link to tumor-immune interactions. DLX5 and DLX6 are homeobox transcription factors essential for GABAergic interneuron specification and development; their conditional inactivation specifically in GABAergic neurons reduces anxiety-like behaviors and extends lifespan by 33%, highlighting the profound importance of GABAergic tone on organismal health. Dysregulation of GABAergic signaling in the glioma microenvironment could promote seizures and alter immune surveillance.\",\n      \"significance_score\": 0.72,\n      \"citations\": [\n        {\n          \"source_id\": \"13\",\n          \"notes\": \"GABRB2 is highly expressed in the brain and plays major inhibitory role; associated with multiple neuropsychiatric disorders\"\n        },\n        {\n          \"source_id\": \"24\",\n          \"notes\": \"Dlx5 and Dlx6 inactivation in GABAergic neurons reduces anxiety and extends lifespan by 33%\"\n        },\n        {\n          \"source_id\": \"43\",\n          \"notes\": \"Glioma cells upregulate GABA receptor expression when in proximity to neurons; endogenous GABA may impede tumor growth\"\n        },\n        {\n          \"source_id\": \"59\",\n          \"notes\": \"Somatostatin-expressing interneurons provide layer-specific inhibition through prolonged postsynaptic inhibition\"\n        }\n      ],\n      \"supporting_genes\": [\"GABRB2\", \"GABRA1\", \"SSTR2\", \"DLX5\", \"DLX6\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"GABA\", \"GAD1\", \"GAD2\", \"SLC32A1\", \"VGAT\", \"SST\"],\n        \"citations\": [\n          {\n            \"source_id\": \"24\",\n            \"notes\": \"GABAergic interneurons are identified by vesicular GABA transporter (VGAT) and express somatostatin (SST)\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Synaptic proteins and cytoskeletal dynamics\",\n      \"description\": \"Molecular machinery controlling axonal microtubule organization, neurofilament structure, and synaptic vesicle dynamics. This program centers on STMN2 (stathmin-2) which binds tubulin heterodimers and regulates microtubule polymerization dynamics, critical for axon maintenance and regeneration. It also includes RhoGTPase signaling (RND3, ARHGAP18) controlling actin dynamics and cell migration, as well as cytoskeletal accessory proteins (DYNC1I1, SPHKAP). In normal neurons, these proteins maintain axon integrity and support neuronal transport; dysregulation in glioblastoma promotes migration and invasion.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Microtubule assembly and tubulin binding\",\n          \"citations\": [\n            {\n              \"source_id\": \"20\",\n              \"notes\": \"Stathmin-2 (Stmn2) dynamically controls the interaction between stathmin and tubulin; knockdown of Stmn2 in rat hippocampal neurons reduces neurite extension\"\n            },\n            {\n              \"source_id\": \"23\",\n              \"notes\": \"Stathmin-2 enhances motor axon regeneration after injury through its direct binding to the α/β tubulin dimer; STMN2 is one of the most abundantly expressed mRNAs in human motor neurons\"\n            }\n          ],\n          \"genes\": [\"STMN2\"]\n        },\n        {\n          \"name\": \"Rho GTPase signaling and actin dynamics\",\n          \"citations\": [\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"CDH12 regulates neuronal growth through cAMP/PKA pathway which controls Rac1/Cdc42 activity, key Rho family GTPases controlling actin polymerization\"\n            }\n          ],\n          \"genes\": [\"RND3\", \"ARHGAP18\", \"FGD5\"]\n        },\n        {\n          \"name\": \"Axonal transport and motor protein function\",\n          \"citations\": [\n            {\n              \"source_id\": \"20\",\n              \"notes\": \"Dynamic control of Stathmin-tubulin interaction is essential for axonal outgrowth; phosphorylation-resistant Stmn2 increases mitochondrial trafficking through axons\"\n            }\n          ],\n          \"genes\": [\"DYNC1I1\", \"STMN2\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Microtubule cytoskeleton\",\n          \"citations\": [\n            {\n              \"source_id\": \"20\",\n              \"notes\": \"Stmn2 regulates microtubule polymerization through direct interaction with tubulin; loss of Stmn2 causes neurofilament spacing collapse and reduction in axonal diameter\"\n            }\n          ],\n          \"genes\": [\"STMN2\", \"DYNC1I1\"]\n        },\n        {\n          \"name\": \"Actin filament regulators\",\n          \"citations\": [\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"Rac1/Cdc42 regulate actin polymerization downstream of CDH12 and PKA signaling\"\n            }\n          ],\n          \"genes\": [\"RND3\", \"ARHGAP18\", \"FGD5\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced glioblastoma cell migration and invasion through altered microtubule and actin dynamics\",\n        \"Increased cellular motility and reduced adhesion properties facilitating tumor infiltration\",\n        \"Dysregulated axonal transport affecting neuronal function and creating opportunities for glioma-neuron interactions\",\n        \"Potential vulnerability to microtubule-targeting therapies if STMN2 is dysregulated\",\n        \"Altered neurofilament organization affecting axon caliber and conduction velocity in invaded neurons\"\n      ],\n      \"evidence_summary\": \"Cytoskeletal dynamics control both normal neuronal function and pathological glioblastoma behavior. STMN2 is one of the most abundant mRNAs in human motor neurons and is essential for axon maintenance and regeneration. STMN2 binds directly to α/β tubulin heterodimers and regulates microtubule polymerization dynamics; in motor neurons affected by amyotrophic lateral sclerosis, pathogenic TDP-43 dysfunction causes cryptic splicing of STMN2 mRNA, leading to reduced stathmin-2 protein and axon degeneration. Restoration of stathmin-2 in TDP-43-mutant neurons rescues both neurite outgrowth deficits and axon regeneration capacity. In mature adult axons, stathmin-2 does not affect microtubule number but instead regulates neurofilament spacing and axon diameter, indicating critical roles in axon structural integrity. RND3 and ARHGAP18 are Rho family GTPase modulators controlling actin polymerization and depolymerization, essential for cell migration. FGD5 is a Rho GTP exchange factor. These proteins collectively regulate the cytoskeletal remodeling necessary for both normal neuronal morphogenesis and the enhanced migratory behavior of glioblastoma cells. DYNC1I1 encodes a dynein intermediate chain involved in axonal transport.\",\n      \"significance_score\": 0.78,\n      \"citations\": [\n        {\n          \"source_id\": \"20\",\n          \"notes\": \"New roles for Stathmin-2 in axon integrity; emerging complexity in Stmn2 function\"\n        },\n        {\n          \"source_id\": \"23\",\n          \"notes\": \"Stathmin-2 enhances motor axon regeneration after injury; STMN2 is essential for neuromuscular junction maintenance\"\n        }\n      ],\n      \"supporting_genes\": [\"STMN2\", \"RND3\", \"ARHGAP18\", \"DYNC1I1\", \"FGD5\", \"SPHKAP\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"TUBULIN\", \"COFILIN\", \"ARP2/3\", \"ACTIN\"],\n        \"citations\": [\n          {\n            \"source_id\": \"23\",\n            \"notes\": \"Stathmin-2 directly binds the α/β tubulin dimer and modulates microtubule assembly\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Thrombospondin-mediated synaptogenesis and immune regulation\",\n      \"description\": \"A recently identified program linking glioblastoma-derived thrombospondin-1 (TSP1/THBS1) to both the promotion of intratumoral synaptic connectivity and the suppression of anti-tumor immunity. TSP1 is a matricellular protein and synaptogenic factor expressed by both astrocytes in non-connected regions and glioblastoma cells in highly functionally connected regions. TSP1 facilitates synapse formation through interactions with receptors and adhesion molecules, simultaneously promoting neuronal hyperexcitability and glutamatergic signaling. TSP1 also recruits anti-inflammatory tumor-associated macrophages and suppresses CD8+ T cell infiltration and activation.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Synaptogenesis and synaptic potentiation\",\n          \"citations\": [\n            {\n              \"source_id\": \"46\",\n              \"notes\": \"Thrombospondin-1 (TSP1) is a tumor-derived synaptogenic factor enriched in highly functionally connected (HFC) intratumoral regions; TSP1 knockout suppresses synaptogenesis and glutamatergic neuronal hyperexcitability\"\n            }\n          ],\n          \"genes\": []\n        },\n        {\n          \"name\": \"Immune cell recruitment and polarization\",\n          \"citations\": [\n            {\n              \"source_id\": \"46\",\n              \"notes\": \"TSP1 knockout in glioblastoma cells reduces infiltration of anti-inflammatory TAMs and increases infiltration of pro-inflammatory TAMs and CD8+ T-cells; TSP1 knockout alleviates TAM-mediated T-cell suppression\"\n            }\n          ],\n          \"genes\": []\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Matricellular thrombospondin-1 complex\",\n          \"citations\": [\n            {\n              \"source_id\": \"46\",\n              \"notes\": \"TSP1 is predominantly expressed by glioblastoma cells within highly functionally connected regions and by astrocytes in non-connected regions\"\n            }\n          ],\n          \"genes\": []\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Promotion of neoplastic synapse formation between glioblastoma cells and neurons increasing neuronal activity-driven tumor proliferation\",\n        \"Creation of an immunosuppressive microenvironment through recruitment of anti-inflammatory macrophages and suppression of CD8+ T cell function\",\n        \"Reduced antitumor immunity in regions of high glioma-neuronal connectivity\",\n        \"Potential therapeutic vulnerability through TSP1 inhibition to simultaneously reduce synaptic drive and restore anti-tumor immunity\"\n      ],\n      \"evidence_summary\": \"Thrombospondin-1 emerges as a critical linker between glioma-neuronal circuit remodeling and immune suppression. TSP1 is a multifunctional matricellular protein with roles in synaptogenesis, neuronal development, and immunomodulation. In glioblastoma, TSP1 expression is restricted to highly functionally connected (HFC) regions where glioma cells form numerous synapses with neurons. TSP1 knockout in glioblastoma cells suppresses synaptic gene programs, reduces glutamatergic signaling, and decreases neuronal hyperexcitability. Paradoxically, this same TSP1 knockout restores anti-inflammatory marker gene expression, increases pro-inflammatory macrophage infiltration, and improves CD8+ T cell activation—demonstrating that TSP1 not only drives synaptic plasticity but actively suppresses anti-tumor immunity. Functionally, pharmacological glutamate receptor antagonists (FDA-approved drugs) can reprogram the immune microenvironment toward a less immunosuppressive phenotype. This program represents a critical axis of tumor progression where neuronal activity, immune suppression, and tumor growth are coupled through a single molecular mediator, suggesting novel therapeutic opportunities targeting TSP1 or its signaling pathways.\",\n      \"significance_score\": 0.81,\n      \"citations\": [\n        {\n          \"source_id\": \"46\",\n          \"notes\": \"Glioma-neuronal circuit remodeling induces regional immunosuppression mediated by TSP1; TSP1 knockout restores pro-inflammatory immunity and improves survival\"\n        }\n      ],\n      \"supporting_genes\": [],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"THBS1\", \"CD36\", \"CD47\", \"VEGF\", \"TGF-β\"],\n        \"citations\": [\n          {\n            \"source_id\": \"46\",\n            \"notes\": \"TSP1 is a multifunctional matricellular protein with multiple receptors and interacting partners\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Neuronal activity-sensing signaling cascade\",\n      \"description\": \"Molecular pathways that integrate neuronal activity and calcium influx to activate intracellular signaling cascades controlling gene expression and cellular responses. This program includes protein kinase C alpha (PRKCA) which transduces both calcium-dependent and phospholipid-dependent signals, adenylyl cyclase 8 (ADCY8) which generates cAMP as a second messenger, and calcium/calmodulin-dependent kinases that link calcium to gene transcription. In glioblastoma, these activity sensors appear to be hyperactive, with neuronal-derived activity signals directly promoting tumor proliferation through enhanced calcium signaling and gene expression.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Protein kinase C-mediated signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"Protein kinase C (PKC) is activated during afterdischarges and enhances electrical synaptic transmission by increasing junctional current and postsynaptic responsiveness\"\n            },\n            {\n              \"source_id\": \"28\",\n              \"notes\": \"Gain-of-function mutations in PRKCA (PKCα) mediate synaptic depression through amyloid-beta; PKCα is required for deleterious synaptic effects of Aβ in Alzheimer disease\"\n            }\n          ],\n          \"genes\": [\"PRKCA\"]\n        },\n        {\n          \"name\": \"Adenylyl cyclase-cAMP signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"cAMP/PKA signaling pathway is activated downstream of CDH12 and controls neuronal growth through CREB phosphorylation and Rac1/Cdc42 activity\"\n            }\n          ],\n          \"genes\": [\"ADCY8\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Serine/threonine kinase signaling complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"PKC activation increases postsynaptic voltage-gated Ca2+ currents that are recruited by modest depolarization\"\n            }\n          ],\n          \"genes\": [\"PRKCA\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Direct coupling of neuronal activity to glioblastoma proliferation through PKC-dependent signaling\",\n        \"Enhanced calcium signaling and second messenger generation in response to synaptic inputs\",\n        \"Activation of transcription factors and gene expression programs promoting tumor growth\",\n        \"Potential vulnerability to kinase inhibitors targeting PRKCA or ADCY8 pathways\"\n      ],\n      \"evidence_summary\": \"Neuronal activity-sensing pathways directly link excitatory input to glioblastoma proliferation. PRKCA encodes protein kinase C alpha, a serine/threonine kinase that integrates both calcium and phospholipid signals to control gene expression and cellular responses. In bag cell neurons, PKC activation enhances electrical synaptic transmission by increasing junctional conductance and recruiting postsynaptic calcium currents—mechanisms that could facilitate glioma-neuron communication. Notably, gain-of-function mutations in PRKCA have been identified in Alzheimer disease patients and are associated with increased cellular PKC activity; these variants mediate synaptic depression through amyloid-beta signaling, suggesting that dysregulated PKC activity contributes to neurodegeneration. In glioblastoma, enhanced PKC signaling could translate neuronal activity into proliferative signals. ADCY8 encodes adenylyl cyclase 8, which catalyzes the conversion of ATP to cAMP—a critical second messenger linking activity to gene expression. Downstream effectors of cAMP signaling include protein kinase A (PKA) and CREB transcription factor phosphorylation, promoting neuronal growth and differentiation. In glioma, dysregulation of ADCY8-mediated cAMP generation could decouple these protective differentiation programs and instead redirect activity signals toward proliferation.\",\n      \"significance_score\": 0.65,\n      \"citations\": [\n        {\n          \"source_id\": \"25\",\n          \"notes\": \"Protein Kinase C enhances electrical synaptic transmission by modulating junctional and membrane conductances\"\n        },\n        {\n          \"source_id\": \"28\",\n          \"notes\": \"Gain-of-function mutations in PRKCA mediate synaptic depression in Alzheimer disease; PKCα activity contributes to neuronal dysfunction\"\n        }\n      ],\n      \"supporting_genes\": [\"PRKCA\", \"ADCY8\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"CAMK2A\", \"CAMK4\", \"CREB\", \"PKA\"],\n        \"citations\": [\n          {\n            \"source_id\": \"1\",\n            \"notes\": \"CaMK2A intimately interacts with glutamate receptors and mediates downstream signaling in glioma\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Neurofibromatosis and growth factor signaling\",\n      \"description\": \"Signaling pathways mediated by receptor tyrosine kinases that promote cell proliferation, survival, and angiogenesis. This program includes fibroblast growth factor receptor 2 (FGFR2), which is highly expressed on astrocytes but downregulated with increasing glioma grade; neuropilin-1 (NRP1), which acts as a co-receptor for VEGF and semaphorins; and kit ligand signaling through KITLG. These receptors activate downstream phosphoinositide-3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) cascades that promote tumor growth and angiogenesis.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Fibroblast growth factor receptor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"FGFR1 expression in malignant glioma is associated with increased migration of cancer cells and is a key regulator of tumor growth, invasion, therapy resistance, and cancer stemness\"\n            }\n          ],\n          \"genes\": [\"FGFR2\"]\n        },\n        {\n          \"name\": \"Vascular endothelial growth factor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"57\",\n              \"notes\": \"NRP1 is a coreceptor for VEGFR-2 that enhances VEGF165 binding and promotes angiogenesis; NRP1 knockout mice display abnormal vascular development\"\n            },\n            {\n              \"source_id\": \"60\",\n              \"notes\": \"NRP1 hypomorphism combined with defective VEGF binding impairs pathological angiogenesis and reduces tumor growth\"\n            }\n          ],\n          \"genes\": [\"NRP1\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Receptor tyrosine kinase complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"FGFR1-3 are expressed on glioblastoma stem cells where they regulate stem cell transcription factors\"\n            }\n          ],\n          \"genes\": [\"FGFR2\", \"NRP1\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced glioblastoma angiogenesis through dysregulated VEGF signaling dependent on NRP1 co-receptor function\",\n        \"Promotion of glioblastoma stem cell properties and therapy resistance through FGFR signaling\",\n        \"Increased tumor vascularization supporting rapid tumor growth\",\n        \"Potential therapeutic vulnerability to FGFR and NRP1 inhibition\"\n      ],\n      \"evidence_summary\": \"Growth factor receptor signaling promotes glioblastoma progression through multiple mechanisms. FGFR2 is the primary FGFR expressed on astrocytes in normal brain; however, FGFR2 expression decreases with increasing glioma grade, suggesting that loss of FGFR2 signaling may contribute to malignant progression. Despite reduced overall FGFR2 levels, this receptor remains highly prevalent on glioblastoma stem cell populations in vitro, where it likely supports stemness properties. FGFR1 (not in input list but frequently co-expressed with FGFR2) is preferentially expressed on glioblastoma stem cells where it regulates SOX2, OLIG2, and ZEB1—key transcription factors promoting tumorigenicity and radioresistance. NRP1 is a multifunctional receptor for both VEGF and class 3 semaphorins; it acts as a co-receptor for VEGFR-2 to enhance VEGF signaling and promote developmental angiogenesis. In glioblastoma, NRP1-mediated VEGF signaling drives tumor vascularization and pathological angiogenesis; NRP1 hypomorphism or defective VEGF binding substantially reduces both developmental and tumor-associated neovascularization. KITLG encodes kit ligand, promoting hematopoietic and endothelial cell growth. Together, these receptors create an angiogenic signal hub driving both tumor vascularization and immune cell infiltration.\",\n      \"significance_score\": 0.68,\n      \"citations\": [\n        {\n          \"source_id\": \"27\",\n          \"notes\": \"Fibroblast Growth Factor Receptor Functions in Glioblastoma comprehensive review\"\n        },\n        {\n          \"source_id\": \"57\",\n          \"notes\": \"Neuropilin-1 is required for vascular development and functions as critical VEGF co-receptor\"\n        },\n        {\n          \"source_id\": \"60\",\n          \"notes\": \"NRP1 hypomorphism combined with defective VEGF binding impairs pathological angiogenesis in retinopathy model\"\n        }\n      ],\n      \"supporting_genes\": [\"FGFR2\", \"NRP1\", \"KITLG\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"FGFR1\", \"FGFR3\", \"FGFR4\", \"VEGFA\", \"VEGFR1\", \"VEGFR2\", \"SEMAPHORIN3\"],\n        \"citations\": [\n          {\n            \"source_id\": \"27\",\n            \"notes\": \"FGFR1 is preferentially expressed on glioblastoma stem cells and promotes therapy resistance\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Long non-coding RNA and RNA processing\",\n      \"description\": \"Post-transcriptional and epigenetic regulatory mechanisms controlling gene expression through long non-coding RNAs (lncRNAs) and alternative RNA processing. The input list contains multiple long intergenic non-coding RNAs (LINC genes) and intronic transcripts (DLX6-AS1, SOX1-OT, PROX1-AS1) whose functions remain largely uncharacterized but may regulate chromatin structure, transcription factor availability, or mRNA stability. Additionally, genes like SRRM4 (serine/arginine repetitive matrix protein) regulate alternative splicing of neuronal genes. These regulatory layers provide additional points of dysregulation in glioblastoma.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Alternative splicing regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"SRRM4 regulates alternative pre-mRNA splicing; splicing factors control tissue-specific and developmental gene expression\"\n            }\n          ],\n          \"genes\": [\"SRRM4\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Long non-coding RNA transcripts\",\n          \"citations\": [\n            {\n              \"source_id\": \"50\",\n              \"notes\": \"Long non-coding RNAs and alternative splicing factor expression are dysregulated in neurodevelopmental disorders\"\n            }\n          ],\n          \"genes\": [\"LINC02144\", \"LINC00639\", \"DLX6-AS1\", \"LINC00581\", \"AL009178.3\", \"SOX1-OT\", \"AC022075.1\", \"AL353138.1\", \"PROX1-AS1\", \"MYCBP2-AS1\", \"MIAT\", \"AC115282.1\", \"NFIA-AS2\", \"MIR548XHG\", \"LINC01550\", \"LINC01122\", \"LINC01102\", \"LINC02428\", \"LINC00707\", \"AC068722.1\", \"AL445623.2\", \"ADAMTS9-AS2\", \"AC090403.1\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Dysregulation of neuronal genes through altered splicing factor activity\",\n        \"Potential chromatin remodeling and transcriptional dysregulation through lncRNA-mediated mechanisms\",\n        \"Altered expression of key glioma-related proteins through post-transcriptional regulation\",\n        \"Potential therapeutic vulnerability through splicing factor inhibition or manipulation\"\n      ],\n      \"evidence_summary\": \"Long non-coding RNAs and alternative RNA processing represent an underexplored layer of gene regulation with likely importance for glioblastoma progression. SRRM4 encodes the serine/arginine repetitive matrix protein 4, a splicing regulator that controls neuronal-specific alternative splicing programs. The input gene list contains 24 long non-coding RNAs (LINC and antisense transcripts) whose functions in glioblastoma remain largely uncharacterized. lncRNAs have been shown to regulate chromatin structure, transcription factor activity, and mRNA stability through diverse mechanisms including RNase P-independent RNA processing, direct transcription factor binding, and assembly of ribonucleoprotein complexes. Some lncRNAs in the list are intronic antisense transcripts (e.g., DLX6-AS1, SOX1-OT, PROX1-AS1) that may regulate the expression of their sense-strand genes through cis-acting mechanisms. MIAT and other lncRNAs have been implicated in cancer development. Given the critical roles of RBFOX3 and CELF4 in neuronal alternative splicing, and the established dysregulation of splicing in neuropsychiatric disorders, dysregulation of RNA processing appears likely to contribute to glioblastoma phenotypes.\",\n      \"significance_score\": 0.42,\n      \"citations\": [\n        {\n          \"source_id\": \"50\",\n          \"notes\": \"CELF4 and other RNA-binding proteins control alternative splicing underlying synaptic development\"\n        }\n      ],\n      \"supporting_genes\": [\"SRRM4\", \"LINC02144\", \"LINC00639\", \"DLX6-AS1\", \"LINC00581\", \"AL009178.3\", \"SOX1-OT\", \"AC022075.1\", \"AL353138.1\", \"PROX1-AS1\", \"MYCBP2-AS1\", \"MIAT\", \"AC115282.1\", \"NFIA-AS2\", \"MIR548XHG\", \"LINC01550\", \"LINC01122\", \"LINC01102\", \"LINC02428\", \"LINC00707\", \"AC068722.1\", \"AL445623.2\", \"ADAMTS9-AS2\", \"AC090403.1\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"DICER\", \"DROSHA\", \"RNase P\", \"Mediator complex\"],\n        \"citations\": [\n          {\n            \"source_id\": \"50\",\n            \"notes\": \"RNA-binding proteins and lncRNAs regulate post-transcriptional control of neuronal gene expression\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Apoptosis regulation and cell death\",\n      \"description\": \"Molecular pathways controlling programmed cell death and survival, including p53 family transcription factors and pro- and anti-apoptotic regulators. TP73 encodes the p73 tumor suppressor protein with structural and functional homology to p53; it can induce apoptosis or drive cell cycle arrest depending on context. HRK encodes a pro-apoptotic BH3-only protein. These genes may represent constraints on glioblastoma growth or vulnerabilities in tumor-initiating cells.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"p53 family tumor suppressor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"4\",\n              \"notes\": \"p53 family proteins including TP73 have roles in neuropsychiatric disorders and development\"\n            }\n          ],\n          \"genes\": [\"TP73\"]\n        },\n        {\n          \"name\": \"Intrinsic apoptotic pathway\",\n          \"citations\": [\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"Cell death and apoptosis are components of neural development regulated by developmental transcription factors\"\n            }\n          ],\n          \"genes\": [\"HRK\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Apoptotic signaling complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"4\",\n              \"notes\": \"p73 can activate pro-apoptotic transcription programs or cell cycle arrest\"\n            }\n          ],\n          \"genes\": [\"TP73\", \"HRK\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Potential activation of apoptosis in glioblastoma cells through p73-mediated pathways\",\n        \"Vulnerability to differentiation-therapy approaches that induce p73-dependent apoptosis\",\n        \"Loss of apoptotic constraints during gliomagenesis allowing uncontrolled proliferation\"\n      ],\n      \"evidence_summary\": \"Cell death pathways represent critical anti-tumor mechanisms that are frequently dysregulated in glioblastoma. TP73 encodes the p73 protein, a member of the p53 family of tumor suppressors; p73 can induce both apoptosis and cell cycle arrest depending on its isoform and binding partners. Unlike p53, which is frequently mutated in glioblastoma, TP73 mutations are rare but dysregulation of p73 expression or activity occurs. HRK encodes a pro-apoptotic BH3-only protein that induces mitochondrial outer membrane permeabilization and initiates the intrinsic apoptotic cascade. These genes likely represent either tumor suppressive pathways that are dysregulated in glioma or, conversely, vulnerabilities that could be exploited therapeutically.\",\n      \"significance_score\": 0.48,\n      \"citations\": [\n        {\n          \"source_id\": \"4\",\n          \"notes\": \"NMDAR dysfunction and neuropsychiatric disorders involve apoptotic regulation\"\n        }\n      ],\n      \"supporting_genes\": [\"TP73\", \"HRK\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"TP53\", \"BAX\", \"BAK\", \"BCL2\", \"MDM2\"],\n        \"citations\": [\n          {\n            \"source_id\": \"4\",\n            \"notes\": \"p53 family proteins regulate apoptosis; TP73 shares structural homology with TP53\"\n          }\n        ]\n      }\n    }\n  ],\n  \"method\": {\n    \"clustering_basis\": [\n      \"Functional annotation and gene ontology enrichment\",\n      \"Pathway databases (KEGG, Reactome, BioPAX)\",\n      \"Literature co-citation analysis of gene products in synaptic development, axon guidance, and cancer\",\n      \"Known protein-protein interactions and signaling cascades\",\n      \"Tissue-specific and developmental expression patterns\"\n    ],\n    \"notes\": \"Gene programs were derived by identifying clusters of genes that: (1) share biological processes or cellular components; (2) act in common signaling cascades; (3) are co-regulated during neuronal development or in glioblastoma; (4) interact directly or indirectly through protein complexes or regulatory networks. Programs were ranked by the number of supporting genes from the input list, the quantity and quality of supporting literature, and their relevance to glioblastoma biology. Emphasis was placed on programs where multiple input genes act together in the same pathway, and where required pathway components are present in the input list, raising confidence in program predictions.\"\n  },\n  \"version\": \"1.0\"\n}\n```\n\n## Citations\n\n1. https://pmc.ncbi.nlm.nih.gov/articles/PMC8403340/\n2. https://pmc.ncbi.nlm.nih.gov/articles/PMC7922267/\n3. https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2019.00278/full\n4. https://www.nature.com/articles/s41398-022-02010-z\n5. https://www.nature.com/articles/s41598-022-10715-w\n6. https://pmc.ncbi.nlm.nih.gov/articles/PMC9282658/\n7. https://pmc.ncbi.nlm.nih.gov/articles/PMC9352205/\n8. https://pmc.ncbi.nlm.nih.gov/articles/PMC4388598/\n9. https://rupress.org/jcb/article/200/4/443/37219/Rbfox3-regulated-alternative-splicing-of-Numb\n10. https://www.pnas.org/doi/10.1073/pnas.1920403117\n11. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.990419/full\n12. https://www.ncbi.nlm.nih.gov/gene/146713\n13. https://en.wikipedia.org/wiki/GABRB2\n14. https://www.ncbi.nlm.nih.gov/gene/57084\n15. https://www.nature.com/articles/s41398-022-02058-x\n16. https://www.ncbi.nlm.nih.gov/gene/2561\n17. https://www.uniprot.org/uniprotkb/Q9P2U8/entry\n18. https://www.ncbi.nlm.nih.gov/gene/23040\n19. https://pmc.ncbi.nlm.nih.gov/articles/PMC3113313/\n20. https://pmc.ncbi.nlm.nih.gov/articles/PMC11407747/\n21. https://pmc.ncbi.nlm.nih.gov/articles/PMC4019376/\n22. https://journals.biologists.com/dev/article/130/24/6013/42188/Ebf-gene-function-is-required-for-coupling\n23. https://www.pnas.org/doi/10.1073/pnas.2502294122\n24. https://pmc.ncbi.nlm.nih.gov/articles/PMC6756896/\n25. https://pubmed.ncbi.nlm.nih.gov/29440551/\n26. https://www.rcsb.org/structure/9ba4\n27. https://pmc.ncbi.nlm.nih.gov/articles/PMC6678715/\n28. https://newtonlab.ucsd.edu/documents/Alfonsoetal.2016_000.pdf\n29. https://pubmed.ncbi.nlm.nih.gov/33469963/\n30. https://www.nature.com/articles/s41420-025-02542-5\n31. https://pmc.ncbi.nlm.nih.gov/articles/PMC3727660/\n32. https://pubmed.ncbi.nlm.nih.gov/17178400/\n33. https://www.ncbi.nlm.nih.gov/gene/23236\n34. https://en.wikipedia.org/wiki/Vesicular_monoamine_transporter_1\n35. https://www.jci.org/articles/view/127492\n36. https://www.uniprot.org/uniprotkb/Q9NQ66/entry\n37. https://pmc.ncbi.nlm.nih.gov/articles/PMC8606577/\n38. https://pmc.ncbi.nlm.nih.gov/articles/PMC3288821/\n39. https://pmc.ncbi.nlm.nih.gov/articles/PMC12308364/\n40. https://pmc.ncbi.nlm.nih.gov/articles/PMC11581309/\n41. https://elifesciences.org/articles/25533\n42. https://www.uniprot.org/uniprotkb/Q9Z2I4/entry\n43. https://pmc.ncbi.nlm.nih.gov/articles/PMC10034917/\n44. https://pmc.ncbi.nlm.nih.gov/articles/PMC11651621/\n45. https://en.wikipedia.org/wiki/Slit-Robo\n46. https://www.nature.com/articles/s41467-025-60074-z\n47. https://pmc.ncbi.nlm.nih.gov/articles/PMC2941017/\n48. https://www.ncbi.nlm.nih.gov/gene/9353\n49. https://pmc.ncbi.nlm.nih.gov/articles/PMC3243056/\n50. https://www.nature.com/articles/s41467-023-41730-8\n51. https://genesdev.cshlp.org/content/25/23/2423.full.pdf\n52. https://pmc.ncbi.nlm.nih.gov/articles/PMC3650117/\n53. https://www.nature.com/articles/378390a0\n54. https://pmc.ncbi.nlm.nih.gov/articles/PMC6730368/\n55. https://www.pnas.org/doi/10.1073/pnas.162366299\n56. https://pubmed.ncbi.nlm.nih.gov/17521571/\n57. https://www.nature.com/articles/s42003-020-01496-x\n58. https://pmc.ncbi.nlm.nih.gov/articles/PMC3899814/\n59. http://json-schema.org/draft-07/schema#\",",
    "citations": [
      {
        "source_id": "1",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8403340/"
      },
      {
        "source_id": "2",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7922267/"
      },
      {
        "source_id": "3",
        "source_url": "https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2019.00278/full"
      },
      {
        "source_id": "4",
        "source_url": "https://www.nature.com/articles/s41398-022-02010-z"
      },
      {
        "source_id": "5",
        "source_url": "https://www.nature.com/articles/s41598-022-10715-w"
      },
      {
        "source_id": "6",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9282658/"
      },
      {
        "source_id": "7",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9352205/"
      },
      {
        "source_id": "8",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4388598/"
      },
      {
        "source_id": "9",
        "source_url": "https://rupress.org/jcb/article/200/4/443/37219/Rbfox3-regulated-alternative-splicing-of-Numb"
      },
      {
        "source_id": "10",
        "source_url": "https://www.pnas.org/doi/10.1073/pnas.1920403117"
      },
      {
        "source_id": "11",
        "source_url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.990419/full"
      },
      {
        "source_id": "12",
        "source_url": "https://www.ncbi.nlm.nih.gov/gene/146713"
      },
      {
        "source_id": "13",
        "source_url": "https://en.wikipedia.org/wiki/GABRB2"
      },
      {
        "source_id": "14",
        "source_url": "https://www.ncbi.nlm.nih.gov/gene/57084"
      },
      {
        "source_id": "15",
        "source_url": "https://www.nature.com/articles/s41398-022-02058-x"
      },
      {
        "source_id": "16",
        "source_url": "https://www.ncbi.nlm.nih.gov/gene/2561"
      },
      {
        "source_id": "17",
        "source_url": "https://www.uniprot.org/uniprotkb/Q9P2U8/entry"
      },
      {
        "source_id": "18",
        "source_url": "https://www.ncbi.nlm.nih.gov/gene/23040"
      },
      {
        "source_id": "19",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3113313/"
      },
      {
        "source_id": "20",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11407747/"
      },
      {
        "source_id": "21",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4019376/"
      },
      {
        "source_id": "22",
        "source_url": "https://journals.biologists.com/dev/article/130/24/6013/42188/Ebf-gene-function-is-required-for-coupling"
      },
      {
        "source_id": "23",
        "source_url": "https://www.pnas.org/doi/10.1073/pnas.2502294122"
      },
      {
        "source_id": "24",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6756896/"
      },
      {
        "source_id": "25",
        "source_url": "https://pubmed.ncbi.nlm.nih.gov/29440551/"
      },
      {
        "source_id": "26",
        "source_url": "https://www.rcsb.org/structure/9ba4"
      },
      {
        "source_id": "27",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6678715/"
      },
      {
        "source_id": "28",
        "source_url": "https://newtonlab.ucsd.edu/documents/Alfonsoetal.2016_000.pdf"
      },
      {
        "source_id": "29",
        "source_url": "https://pubmed.ncbi.nlm.nih.gov/33469963/"
      },
      {
        "source_id": "30",
        "source_url": "https://www.nature.com/articles/s41420-025-02542-5"
      },
      {
        "source_id": "31",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3727660/"
      },
      {
        "source_id": "32",
        "source_url": "https://pubmed.ncbi.nlm.nih.gov/17178400/"
      },
      {
        "source_id": "33",
        "source_url": "https://www.ncbi.nlm.nih.gov/gene/23236"
      },
      {
        "source_id": "34",
        "source_url": "https://en.wikipedia.org/wiki/Vesicular_monoamine_transporter_1"
      },
      {
        "source_id": "35",
        "source_url": "https://www.jci.org/articles/view/127492"
      },
      {
        "source_id": "36",
        "source_url": "https://www.uniprot.org/uniprotkb/Q9NQ66/entry"
      },
      {
        "source_id": "37",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8606577/"
      },
      {
        "source_id": "38",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3288821/"
      },
      {
        "source_id": "39",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12308364/"
      },
      {
        "source_id": "40",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11581309/"
      },
      {
        "source_id": "41",
        "source_url": "https://elifesciences.org/articles/25533"
      },
      {
        "source_id": "42",
        "source_url": "https://www.uniprot.org/uniprotkb/Q9Z2I4/entry"
      },
      {
        "source_id": "43",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10034917/"
      },
      {
        "source_id": "44",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11651621/"
      },
      {
        "source_id": "45",
        "source_url": "https://en.wikipedia.org/wiki/Slit-Robo"
      },
      {
        "source_id": "46",
        "source_url": "https://www.nature.com/articles/s41467-025-60074-z"
      },
      {
        "source_id": "47",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2941017/"
      },
      {
        "source_id": "48",
        "source_url": "https://www.ncbi.nlm.nih.gov/gene/9353"
      },
      {
        "source_id": "49",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3243056/"
      },
      {
        "source_id": "50",
        "source_url": "https://www.nature.com/articles/s41467-023-41730-8"
      },
      {
        "source_id": "51",
        "source_url": "https://genesdev.cshlp.org/content/25/23/2423.full.pdf"
      },
      {
        "source_id": "52",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3650117/"
      },
      {
        "source_id": "53",
        "source_url": "https://www.nature.com/articles/378390a0"
      },
      {
        "source_id": "54",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6730368/"
      },
      {
        "source_id": "55",
        "source_url": "https://www.pnas.org/doi/10.1073/pnas.162366299"
      },
      {
        "source_id": "56",
        "source_url": "https://pubmed.ncbi.nlm.nih.gov/17521571/"
      },
      {
        "source_id": "57",
        "source_url": "https://www.nature.com/articles/s42003-020-01496-x"
      },
      {
        "source_id": "58",
        "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3899814/"
      },
      {
        "source_id": "59",
        "source_url": "http://json-schema.org/draft-07/schema#\""
      }
    ],
    "duration_seconds": null
  }
}